{"transactions":[{"id":811641,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-09T21:15:06.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":17578,"price":2.56,"value":44999.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of an annual cash retainer for service on the Issuer's Board of Directors in the aggregate amount of $45,000. The RSUs vest 25% upon grant and 25% on each of June 30, 2026, September 30, 2026 and December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":17578,"source":{"system":"sec-edgar","filing":"0001886431-26-000004","document":"form4-04092026_050401.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886431/000188643126000004/form4-04092026_050401.xml","form_type":"4"}},{"id":856407,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-03-06T21:11:49.000Z","date":"2026-03-05","kind":"sale","planned":true,"acquired":false,"shares":153,"price":326.24,"value":49914.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F10","text":"This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $326.01 to $326.40. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":20569,"source":{"system":"sec-edgar","filing":"0001735276-26-000059","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000059/edgardoc.xml","form_type":"4"}},{"id":856406,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-03-06T21:11:49.000Z","date":"2026-03-05","kind":"sale","planned":true,"acquired":false,"shares":148,"price":324.6,"value":48040.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F10","text":"This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.36 to $325.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":20722,"source":{"system":"sec-edgar","filing":"0001735276-26-000059","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000059/edgardoc.xml","form_type":"4"}},{"id":856405,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-03-06T21:11:49.000Z","date":"2026-03-05","kind":"sale","planned":true,"acquired":false,"shares":233,"price":323.25,"value":75317.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F10","text":"This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.81 to $323.65. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":20870,"source":{"system":"sec-edgar","filing":"0001735276-26-000059","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000059/edgardoc.xml","form_type":"4"}},{"id":856404,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-03-06T21:11:49.000Z","date":"2026-03-05","kind":"sale","planned":true,"acquired":false,"shares":124,"price":321.81,"value":39904.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F10","text":"This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.43 to $322.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":21103,"source":{"system":"sec-edgar","filing":"0001735276-26-000059","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000059/edgardoc.xml","form_type":"4"}},{"id":856403,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-03-06T21:11:49.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":57,"price":325.67,"value":18563.19,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.40 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":21227,"source":{"system":"sec-edgar","filing":"0001735276-26-000059","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000059/edgardoc.xml","form_type":"4"}},{"id":856402,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-03-06T21:11:49.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":75,"price":324.88,"value":24366.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.39 to $325.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":21284,"source":{"system":"sec-edgar","filing":"0001735276-26-000059","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000059/edgardoc.xml","form_type":"4"}},{"id":856401,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-03-06T21:11:49.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":210,"price":323.84,"value":68006.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.38 to $324.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":21359,"source":{"system":"sec-edgar","filing":"0001735276-26-000059","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000059/edgardoc.xml","form_type":"4"}},{"id":856400,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-03-06T21:11:49.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":96,"price":323.01,"value":31008.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.36 to $323.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":21569,"source":{"system":"sec-edgar","filing":"0001735276-26-000059","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000059/edgardoc.xml","form_type":"4"}},{"id":856399,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-03-06T21:11:49.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":79,"price":321.82,"value":25423.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.34 to $322.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":21665,"source":{"system":"sec-edgar","filing":"0001735276-26-000059","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000059/edgardoc.xml","form_type":"4"}},{"id":856398,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-03-06T21:11:49.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":59,"price":320.81,"value":18927.79,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.33 to $321.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":21744,"source":{"system":"sec-edgar","filing":"0001735276-26-000059","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000059/edgardoc.xml","form_type":"4"}},{"id":856397,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-03-06T21:11:49.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":28,"price":320.01,"value":8960.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.28 to $320.28. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":21803,"source":{"system":"sec-edgar","filing":"0001735276-26-000059","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000059/edgardoc.xml","form_type":"4"}},{"id":856396,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-03-06T21:11:49.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":29,"price":319.03,"value":9251.87,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.27 to $319.27. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":21831,"source":{"system":"sec-edgar","filing":"0001735276-26-000059","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000059/edgardoc.xml","form_type":"4"}},{"id":862490,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Stock Option  (right to buy)","published_at":"2026-03-05T00:30:38.000Z","date":"2026-03-02","kind":"grant","planned":true,"acquired":true,"shares":8105,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F19","text":"The stock option vests as to 25% of the shares on the first anniversary of the grant date and the remaining shares vest in equal installments at the end of each successive three-month period thereafter until the fourth anniversary of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date."}],"balance_after":8105,"derivative":{"exercise_price":325.07,"expiration_date":"2036-03-02","underlying":"Common Stock","underlying_shares":8105},"source":{"system":"sec-edgar","filing":"0001735276-26-000051","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000051/edgardoc.xml","form_type":"4"}},{"id":862489,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-03-05T00:30:38.000Z","date":"2026-03-03","kind":"sale","planned":true,"acquired":false,"shares":359,"price":321.58,"value":115447.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F13","text":"This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.36 to $321.84. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":21860,"source":{"system":"sec-edgar","filing":"0001735276-26-000051","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000051/edgardoc.xml","form_type":"4"}},{"id":862488,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-03-05T00:30:38.000Z","date":"2026-03-03","kind":"sale","planned":true,"acquired":false,"shares":722,"price":320.51,"value":231408.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F13","text":"This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.04 to $320.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":22219,"source":{"system":"sec-edgar","filing":"0001735276-26-000051","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000051/edgardoc.xml","form_type":"4"}},{"id":862487,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-03-05T00:30:38.000Z","date":"2026-03-03","kind":"sale","planned":true,"acquired":false,"shares":282,"price":318.62,"value":89850.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F13","text":"This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.25 to $318.90. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":22941,"source":{"system":"sec-edgar","filing":"0001735276-26-000051","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000051/edgardoc.xml","form_type":"4"}},{"id":862486,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-03-05T00:30:38.000Z","date":"2026-03-03","kind":"sale","planned":true,"acquired":false,"shares":289,"price":316.55,"value":91482.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F13","text":"This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $316.51 to $317.12. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23223,"source":{"system":"sec-edgar","filing":"0001735276-26-000051","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000051/edgardoc.xml","form_type":"4"}},{"id":862485,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-03-05T00:30:38.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":37,"price":332.64,"value":12307.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $332.34 to $332.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23512,"source":{"system":"sec-edgar","filing":"0001735276-26-000051","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000051/edgardoc.xml","form_type":"4"}},{"id":862484,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-03-05T00:30:38.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":94,"price":331.93,"value":31201.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $331.32 to $332.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23549,"source":{"system":"sec-edgar","filing":"0001735276-26-000051","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000051/edgardoc.xml","form_type":"4"}},{"id":862483,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-03-05T00:30:38.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":81,"price":330.85,"value":26798.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $330.30 to $331.30. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23643,"source":{"system":"sec-edgar","filing":"0001735276-26-000051","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000051/edgardoc.xml","form_type":"4"}},{"id":862482,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-03-05T00:30:38.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":170,"price":329.71,"value":56050.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $329.29 to $330.29. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23724,"source":{"system":"sec-edgar","filing":"0001735276-26-000051","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000051/edgardoc.xml","form_type":"4"}},{"id":862481,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-03-05T00:30:38.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":100,"price":328.71,"value":32871.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $328.28 to $329.26. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23894,"source":{"system":"sec-edgar","filing":"0001735276-26-000051","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000051/edgardoc.xml","form_type":"4"}},{"id":862480,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-03-05T00:30:38.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":329,"price":327.67,"value":107803.43,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $327.24 to $328.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23994,"source":{"system":"sec-edgar","filing":"0001735276-26-000051","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000051/edgardoc.xml","form_type":"4"}},{"id":862479,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-03-05T00:30:38.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":392,"price":326.81,"value":128109.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $326.23 to $327.23. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":24323,"source":{"system":"sec-edgar","filing":"0001735276-26-000051","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000051/edgardoc.xml","form_type":"4"}},{"id":862478,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-03-05T00:30:38.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":258,"price":325.63,"value":84012.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.21 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":24715,"source":{"system":"sec-edgar","filing":"0001735276-26-000051","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000051/edgardoc.xml","form_type":"4"}},{"id":862477,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-03-05T00:30:38.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":90,"price":324.65,"value":29218.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.20 to $325.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":24973,"source":{"system":"sec-edgar","filing":"0001735276-26-000051","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000051/edgardoc.xml","form_type":"4"}},{"id":862476,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-03-05T00:30:38.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":47,"price":323.62,"value":15210.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.16 to $324.15. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":25063,"source":{"system":"sec-edgar","filing":"0001735276-26-000051","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000051/edgardoc.xml","form_type":"4"}},{"id":862475,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-03-05T00:30:38.000Z","date":"2026-03-02","kind":"grant","planned":true,"acquired":true,"shares":3688,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date."}],"balance_after":25110,"source":{"system":"sec-edgar","filing":"0001735276-26-000051","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000051/edgardoc.xml","form_type":"4"}},{"id":874608,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-03-02T21:30:17.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on February 26, 2027, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":65000,"derivative":{"exercise_price":1.65,"expiration_date":"2036-02-25","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001886431-26-000002","document":"form4-03022026_040313.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886431/000188643126000002/form4-03022026_040313.xml","form_type":"4"}},{"id":882353,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-02-25T21:17:11.000Z","date":"2026-02-23","kind":"grant","planned":false,"acquired":true,"shares":158,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 23, 2026, the People, Culture, and Compensation Committee of the issuer approved the issuance of shares of Company common stock having an aggregate value of USD $100,000 to each employee who completes 20 consecutive years of employment.  The shares issued and reported here on Form 4, net of the minimum statutory tax liability, were issued to the reporting person in recognition of 20 years of continuous employment on December 5, 2025."}],"balance_after":21422,"source":{"system":"sec-edgar","filing":"0001735276-26-000032","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000032/edgardoc.xml","form_type":"4"}},{"id":901554,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-02-18T00:26:59.000Z","date":"2026-02-17","kind":"sale","planned":true,"acquired":false,"shares":2041,"price":331.9606,"value":677531.5846,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $329.10 to $334.51. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":21264,"source":{"system":"sec-edgar","filing":"0001735276-26-000026","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000026/edgardoc.xml","form_type":"4"}},{"id":901553,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-02-18T00:26:59.000Z","date":"2026-02-13","kind":"sale","planned":true,"acquired":false,"shares":1959,"price":310.0808,"value":607448.2872,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $302.55 to $314.60. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23305,"source":{"system":"sec-edgar","filing":"0001735276-26-000026","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000026/edgardoc.xml","form_type":"4"}},{"id":901552,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-02-18T00:26:59.000Z","date":"2026-02-12","kind":"grant","planned":true,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 27, 2023, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of forty (40) percent of the shares subject to the PSU based on the issuer publicly reporting the achievement of non-GAAP operating income for fiscal year 2025 on February 12, 2026, as determined by the People, Culture and Compensation Committee of the Issuer Board of Directors."}],"balance_after":25264,"source":{"system":"sec-edgar","filing":"0001735276-26-000026","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000026/edgardoc.xml","form_type":"4"}},{"id":939392,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-01-14T21:21:52.000Z","date":"2026-01-13","kind":"sale","planned":true,"acquired":false,"shares":122,"price":374.33,"value":45668.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F22","text":"This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F28","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $374.28 to $374.66. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":21264,"source":{"system":"sec-edgar","filing":"0001735276-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000011/edgardoc.xml","form_type":"4"}},{"id":939391,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-01-14T21:21:52.000Z","date":"2026-01-13","kind":"sale","planned":true,"acquired":false,"shares":280,"price":372.93,"value":104420.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F22","text":"This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F27","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $372.70 to $373.11. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":21386,"source":{"system":"sec-edgar","filing":"0001735276-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000011/edgardoc.xml","form_type":"4"}},{"id":939390,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-01-14T21:21:52.000Z","date":"2026-01-13","kind":"sale","planned":true,"acquired":false,"shares":485,"price":371.24,"value":180051.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F22","text":"This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F26","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $370.52 to $371.47. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":21666,"source":{"system":"sec-edgar","filing":"0001735276-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000011/edgardoc.xml","form_type":"4"}},{"id":939389,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-01-14T21:21:52.000Z","date":"2026-01-13","kind":"sale","planned":true,"acquired":false,"shares":644,"price":370,"value":238280.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F22","text":"This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F25","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $369.36 to $370.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":22151,"source":{"system":"sec-edgar","filing":"0001735276-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000011/edgardoc.xml","form_type":"4"}},{"id":939388,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-01-14T21:21:52.000Z","date":"2026-01-13","kind":"sale","planned":true,"acquired":false,"shares":562,"price":368.76,"value":207243.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F22","text":"This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F24","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $368.25 to $369.23. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":22795,"source":{"system":"sec-edgar","filing":"0001735276-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000011/edgardoc.xml","form_type":"4"}},{"id":939387,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-01-14T21:21:52.000Z","date":"2026-01-13","kind":"sale","planned":true,"acquired":false,"shares":197,"price":367.52,"value":72401.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F22","text":"This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F23","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $367.18 to $367.96. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23357,"source":{"system":"sec-edgar","filing":"0001735276-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000011/edgardoc.xml","form_type":"4"}},{"id":939386,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-01-14T21:21:52.000Z","date":"2026-01-12","kind":"sale","planned":true,"acquired":false,"shares":15,"price":377.82,"value":5667.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."}],"balance_after":23554,"source":{"system":"sec-edgar","filing":"0001735276-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000011/edgardoc.xml","form_type":"4"}},{"id":939385,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-01-14T21:21:52.000Z","date":"2026-01-12","kind":"sale","planned":true,"acquired":false,"shares":19,"price":375.65,"value":7137.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."}],"balance_after":23569,"source":{"system":"sec-edgar","filing":"0001735276-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000011/edgardoc.xml","form_type":"4"}},{"id":939384,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-01-14T21:21:52.000Z","date":"2026-01-12","kind":"sale","planned":true,"acquired":false,"shares":14,"price":374.44,"value":5242.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F21","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $374.08 to $374.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23588,"source":{"system":"sec-edgar","filing":"0001735276-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000011/edgardoc.xml","form_type":"4"}},{"id":939383,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-01-14T21:21:52.000Z","date":"2026-01-12","kind":"sale","planned":true,"acquired":false,"shares":2,"price":372.46,"value":744.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F20","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $372.35 to $372.50. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23602,"source":{"system":"sec-edgar","filing":"0001735276-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000011/edgardoc.xml","form_type":"4"}},{"id":939382,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-01-14T21:21:52.000Z","date":"2026-01-12","kind":"sale","planned":true,"acquired":false,"shares":19,"price":370.87,"value":7046.53,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F19","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $370.43 to $371.23. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23604,"source":{"system":"sec-edgar","filing":"0001735276-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000011/edgardoc.xml","form_type":"4"}},{"id":939381,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-01-14T21:21:52.000Z","date":"2026-01-12","kind":"sale","planned":true,"acquired":false,"shares":40,"price":369.48,"value":14779.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F18","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $369.13 to $369.93. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23623,"source":{"system":"sec-edgar","filing":"0001735276-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000011/edgardoc.xml","form_type":"4"}},{"id":939380,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-01-14T21:21:52.000Z","date":"2026-01-12","kind":"sale","planned":true,"acquired":false,"shares":92,"price":368.62,"value":33913.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $368.09 to $369.08. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23663,"source":{"system":"sec-edgar","filing":"0001735276-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000011/edgardoc.xml","form_type":"4"}},{"id":939379,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-01-14T21:21:52.000Z","date":"2026-01-12","kind":"sale","planned":true,"acquired":false,"shares":41,"price":367.4,"value":15063.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $367.04 to $368.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23755,"source":{"system":"sec-edgar","filing":"0001735276-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000011/edgardoc.xml","form_type":"4"}},{"id":939378,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-01-14T21:21:52.000Z","date":"2026-01-12","kind":"sale","planned":true,"acquired":false,"shares":50,"price":366.41,"value":18320.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $366.03 to $366.96. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23796,"source":{"system":"sec-edgar","filing":"0001735276-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000011/edgardoc.xml","form_type":"4"}},{"id":939377,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-01-14T21:21:52.000Z","date":"2026-01-12","kind":"sale","planned":true,"acquired":false,"shares":220,"price":365.56,"value":80423.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $365.01 to $366.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23846,"source":{"system":"sec-edgar","filing":"0001735276-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000011/edgardoc.xml","form_type":"4"}},{"id":939376,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-01-14T21:21:52.000Z","date":"2026-01-12","kind":"sale","planned":true,"acquired":false,"shares":199,"price":364.83,"value":72601.17,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $364.00 to $365.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":24066,"source":{"system":"sec-edgar","filing":"0001735276-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000011/edgardoc.xml","form_type":"4"}},{"id":939375,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-01-14T21:21:52.000Z","date":"2026-01-12","kind":"sale","planned":true,"acquired":false,"shares":47,"price":363.55,"value":17086.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $362.99 to $363.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":24265,"source":{"system":"sec-edgar","filing":"0001735276-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000011/edgardoc.xml","form_type":"4"}},{"id":939374,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-01-14T21:21:52.000Z","date":"2026-01-12","kind":"sale","planned":true,"acquired":false,"shares":73,"price":362.38,"value":26453.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $361.93 to $362.92. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":24312,"source":{"system":"sec-edgar","filing":"0001735276-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000011/edgardoc.xml","form_type":"4"}},{"id":939373,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-01-14T21:21:52.000Z","date":"2026-01-12","kind":"sale","planned":true,"acquired":false,"shares":98,"price":361.45,"value":35422.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $360.90 to $361.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":24385,"source":{"system":"sec-edgar","filing":"0001735276-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000011/edgardoc.xml","form_type":"4"}},{"id":939372,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-01-14T21:21:52.000Z","date":"2026-01-12","kind":"sale","planned":true,"acquired":false,"shares":155,"price":360.22,"value":55834.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $359.79 to $360.79. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":24483,"source":{"system":"sec-edgar","filing":"0001735276-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000011/edgardoc.xml","form_type":"4"}},{"id":939371,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-01-14T21:21:52.000Z","date":"2026-01-12","kind":"sale","planned":true,"acquired":false,"shares":85,"price":359.14,"value":30526.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $358.69 to $359.66. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":24638,"source":{"system":"sec-edgar","filing":"0001735276-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000011/edgardoc.xml","form_type":"4"}},{"id":939370,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-01-14T21:21:52.000Z","date":"2026-01-12","kind":"sale","planned":true,"acquired":false,"shares":123,"price":358.18,"value":44056.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $357.68 to $358.68. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":24723,"source":{"system":"sec-edgar","filing":"0001735276-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000011/edgardoc.xml","form_type":"4"}},{"id":939369,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-01-14T21:21:52.000Z","date":"2026-01-12","kind":"sale","planned":true,"acquired":false,"shares":96,"price":357.17,"value":34288.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $356.63 to $357.63. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":24846,"source":{"system":"sec-edgar","filing":"0001735276-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000011/edgardoc.xml","form_type":"4"}},{"id":939368,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-01-14T21:21:52.000Z","date":"2026-01-12","kind":"sale","planned":true,"acquired":false,"shares":41,"price":356.09,"value":14599.69,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $356.62 to $356.61. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":24942,"source":{"system":"sec-edgar","filing":"0001735276-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000011/edgardoc.xml","form_type":"4"}},{"id":939367,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-01-14T21:21:52.000Z","date":"2026-01-12","kind":"sale","planned":true,"acquired":false,"shares":42,"price":355.16,"value":14916.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $354.54 to $355.53. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":24983,"source":{"system":"sec-edgar","filing":"0001735276-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000011/edgardoc.xml","form_type":"4"}},{"id":939366,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-01-14T21:21:52.000Z","date":"2026-01-12","kind":"sale","planned":true,"acquired":false,"shares":39,"price":353.95,"value":13804.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $353.53 to $354.41. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":25025,"source":{"system":"sec-edgar","filing":"0001735276-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000011/edgardoc.xml","form_type":"4"}},{"id":939365,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2026-01-14T21:21:52.000Z","date":"2026-01-11","kind":"grant","planned":true,"acquired":true,"shares":3800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 1, 2024, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of forty (40) percent of the shares subject to the PSU based on the issuer publicly reporting $2.5 billion in annual net product revenue in accordance with GAAP, as determined by the People, Culture and Compensation Committee of the Issuer Board of Directors on January 11, 2026."}],"balance_after":25064,"source":{"system":"sec-edgar","filing":"0001735276-26-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000011/edgardoc.xml","form_type":"4"}},{"id":994280,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Stock Option  (right to buy)","published_at":"2025-11-19T21:05:28.000Z","date":"2025-11-17","kind":"exercise","planned":true,"acquired":false,"shares":8161,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"This stock option was fully vested and exercisable as of December 1, 2021."}],"balance_after":839,"derivative":{"exercise_price":119.13,"expiration_date":"2028-03-01","underlying":"Common Stock","underlying_shares":8161},"source":{"system":"sec-edgar","filing":"0001735276-25-000123","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000123/edgardoc.xml","form_type":"4"}},{"id":994279,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-11-19T21:05:28.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":295,"price":463.08,"value":136608.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $462.82 to $463.46. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":21264,"source":{"system":"sec-edgar","filing":"0001735276-25-000123","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000123/edgardoc.xml","form_type":"4"}},{"id":994278,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-11-19T21:05:28.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":323,"price":461.96,"value":149213.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $461.50 to $462.39. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":21559,"source":{"system":"sec-edgar","filing":"0001735276-25-000123","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000123/edgardoc.xml","form_type":"4"}},{"id":994277,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-11-19T21:05:28.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":707,"price":460.84,"value":325813.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $460.46 to $461.40. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":21882,"source":{"system":"sec-edgar","filing":"0001735276-25-000123","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000123/edgardoc.xml","form_type":"4"}},{"id":994276,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-11-19T21:05:28.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":622,"price":459.89,"value":286051.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $459.40 to $460.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":22589,"source":{"system":"sec-edgar","filing":"0001735276-25-000123","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000123/edgardoc.xml","form_type":"4"}},{"id":994275,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-11-19T21:05:28.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":794,"price":458.41,"value":363977.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $458.01 to $458.94. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23211,"source":{"system":"sec-edgar","filing":"0001735276-25-000123","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000123/edgardoc.xml","form_type":"4"}},{"id":994274,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-11-19T21:05:28.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":262,"price":457.39,"value":119836.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $457.00 to $457.98. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":24005,"source":{"system":"sec-edgar","filing":"0001735276-25-000123","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000123/edgardoc.xml","form_type":"4"}},{"id":994273,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-11-19T21:05:28.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":364,"price":456.25,"value":166075.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $455.97 to $456.94. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":24267,"source":{"system":"sec-edgar","filing":"0001735276-25-000123","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000123/edgardoc.xml","form_type":"4"}},{"id":994272,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-11-19T21:05:28.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":368,"price":455.24,"value":167528.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $454.92 to $455.45. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":24631,"source":{"system":"sec-edgar","filing":"0001735276-25-000123","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000123/edgardoc.xml","form_type":"4"}},{"id":994271,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-11-19T21:05:28.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":129,"price":451.51,"value":58244.79,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $451.41 to $451.84. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":24999,"source":{"system":"sec-edgar","filing":"0001735276-25-000123","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000123/edgardoc.xml","form_type":"4"}},{"id":994270,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-11-19T21:05:28.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":96,"price":450.09,"value":43208.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025."}],"balance_after":25128,"source":{"system":"sec-edgar","filing":"0001735276-25-000123","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000123/edgardoc.xml","form_type":"4"}},{"id":994269,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-11-19T21:05:28.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":8168,"price":449,"value":3667432.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025."}],"balance_after":25224,"source":{"system":"sec-edgar","filing":"0001735276-25-000123","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000123/edgardoc.xml","form_type":"4"}},{"id":994268,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-11-19T21:05:28.000Z","date":"2025-11-17","kind":"exercise","planned":true,"acquired":true,"shares":8161,"price":119.13,"value":972219.93,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025."}],"balance_after":33392,"source":{"system":"sec-edgar","filing":"0001735276-25-000123","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000123/edgardoc.xml","form_type":"4"}},{"id":1025149,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-10-03T21:13:08.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":3,"price":457.64,"value":1372.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."}],"balance_after":25231,"source":{"system":"sec-edgar","filing":"0001735276-25-000114","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000114/edgardoc.xml","form_type":"4"}},{"id":1025148,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-10-03T21:13:08.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":122,"price":457.43,"value":55806.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."}],"balance_after":25234,"source":{"system":"sec-edgar","filing":"0001735276-25-000114","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000114/edgardoc.xml","form_type":"4"}},{"id":1025147,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-10-03T21:13:08.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":60,"price":455.82,"value":27349.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $455.42 to $456.09. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":25356,"source":{"system":"sec-edgar","filing":"0001735276-25-000114","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000114/edgardoc.xml","form_type":"4"}},{"id":1025146,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-10-03T21:13:08.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":203,"price":454.84,"value":92332.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $454.38 to $455.34. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":25416,"source":{"system":"sec-edgar","filing":"0001735276-25-000114","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000114/edgardoc.xml","form_type":"4"}},{"id":1025145,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-10-03T21:13:08.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":273,"price":453.77,"value":123879.21,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $453.37 to $454.37. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":25619,"source":{"system":"sec-edgar","filing":"0001735276-25-000114","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000114/edgardoc.xml","form_type":"4"}},{"id":1025144,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-10-03T21:13:08.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":555,"price":452.69,"value":251242.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $452.33 to $453.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":25892,"source":{"system":"sec-edgar","filing":"0001735276-25-000114","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000114/edgardoc.xml","form_type":"4"}},{"id":1025143,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-10-03T21:13:08.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":276,"price":451.86,"value":124713.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $451.31 to $452.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":26447,"source":{"system":"sec-edgar","filing":"0001735276-25-000114","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000114/edgardoc.xml","form_type":"4"}},{"id":1025142,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-10-03T21:13:08.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":449,"price":450.81,"value":202413.69,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $450.29 to $451.29. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":26723,"source":{"system":"sec-edgar","filing":"0001735276-25-000114","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000114/edgardoc.xml","form_type":"4"}},{"id":1025141,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-10-03T21:13:08.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":207,"price":449.79,"value":93106.53,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $449.26 to $450.26. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":27172,"source":{"system":"sec-edgar","filing":"0001735276-25-000114","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000114/edgardoc.xml","form_type":"4"}},{"id":1025140,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-10-03T21:13:08.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":150,"price":448.77,"value":67315.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $448.25 to $449.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":27379,"source":{"system":"sec-edgar","filing":"0001735276-25-000114","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000114/edgardoc.xml","form_type":"4"}},{"id":1025139,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-10-03T21:13:08.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":47,"price":447.92,"value":21052.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $447.21 to $448.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":27529,"source":{"system":"sec-edgar","filing":"0001735276-25-000114","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000114/edgardoc.xml","form_type":"4"}},{"id":1025138,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-10-03T21:13:08.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":96,"price":446.53,"value":42866.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $446.19 to $447.19. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":27576,"source":{"system":"sec-edgar","filing":"0001735276-25-000114","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000114/edgardoc.xml","form_type":"4"}},{"id":1025137,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-10-03T21:13:08.000Z","date":"2025-10-01","kind":"grant","planned":false,"acquired":true,"shares":2851,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 1, 2024, the reporting person was granted a PSU under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of thirty (30) percent of the shares subject to the PSU based on the issuer publicly reporting the initiation of a Phase 3 clinical study in a prevalent indication, as determined by the PC&C Committee on October 1, 2025."}],"balance_after":27672,"source":{"system":"sec-edgar","filing":"0001735276-25-000114","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000114/edgardoc.xml","form_type":"4"}},{"id":1025136,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-10-03T21:13:08.000Z","date":"2025-10-01","kind":"grant","planned":false,"acquired":true,"shares":2102,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 24, 2021, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of four specified performance measures. The shares reported were issued to the reporting person upon vesting of one-quarter of the shares subject to the PSU based on the issuer publicly reporting the initiation of a Phase 3 clinical study of an RNAi therapeutic in development to treat a prevalent disease, as determined by the People, Culture and Compensation (PC&C) Committee of the Issuer Board of Directors on October 1, 2025."}],"balance_after":24821,"source":{"system":"sec-edgar","filing":"0001735276-25-000114","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000114/edgardoc.xml","form_type":"4"}},{"id":1062559,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-08-19T21:26:36.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":12,"price":455.82,"value":5469.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $455.65 to $456.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":22719,"source":{"system":"sec-edgar","filing":"0001735276-25-000088","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000088/edgardoc.xml","form_type":"4"}},{"id":1062558,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-08-19T21:26:36.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":241,"price":454.84,"value":109616.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $454.58 to $455.55. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":22731,"source":{"system":"sec-edgar","filing":"0001735276-25-000088","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000088/edgardoc.xml","form_type":"4"}},{"id":1062557,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-08-19T21:26:36.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":543,"price":454.04,"value":246543.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $453.50 to $454.45. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":22972,"source":{"system":"sec-edgar","filing":"0001735276-25-000088","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000088/edgardoc.xml","form_type":"4"}},{"id":1062556,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-08-19T21:26:36.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":329,"price":452.96,"value":149023.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $452.49 to $453.49. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23515,"source":{"system":"sec-edgar","filing":"0001735276-25-000088","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000088/edgardoc.xml","form_type":"4"}},{"id":1062555,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-08-19T21:26:36.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":103,"price":451.99,"value":46554.97,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $451.48 to $452.48. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23844,"source":{"system":"sec-edgar","filing":"0001735276-25-000088","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000088/edgardoc.xml","form_type":"4"}},{"id":1062554,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-08-19T21:26:36.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":39,"price":450.92,"value":17585.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $450.42 to $451.39. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23947,"source":{"system":"sec-edgar","filing":"0001735276-25-000088","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000088/edgardoc.xml","form_type":"4"}},{"id":1062553,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-08-19T21:26:36.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":90,"price":449.92,"value":40492.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $449.21 to $450.16. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":23986,"source":{"system":"sec-edgar","filing":"0001735276-25-000088","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000088/edgardoc.xml","form_type":"4"}},{"id":1062552,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-08-19T21:26:36.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":39,"price":447.98,"value":17471.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $447.53 to $448.45. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":24076,"source":{"system":"sec-edgar","filing":"0001735276-25-000088","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000088/edgardoc.xml","form_type":"4"}},{"id":1062551,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-08-19T21:26:36.000Z","date":"2025-08-15","kind":"grant","planned":false,"acquired":true,"shares":2851,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 1, 2024, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of thirty (30) percent of the shares subject to the PSU based on the achievement of a clinical milestone, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on August 15, 2025."}],"balance_after":24115,"source":{"system":"sec-edgar","filing":"0001735276-25-000088","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000088/edgardoc.xml","form_type":"4"}},{"id":1095923,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CSO & EVP, Head of Research"}}],"security":"Common Stock","published_at":"2025-07-02T20:26:48.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":7763,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date."}],"balance_after":21264,"source":{"system":"sec-edgar","filing":"0001735276-25-000077","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000077/edgardoc.xml","form_type":"4"}},{"id":1106502,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-18T20:45:12.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on February 20, 2026, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":45000,"derivative":{"exercise_price":0.57,"expiration_date":"2035-02-19","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001415889-25-017698","document":"form4-06182025_040608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886431/000141588925017698/form4-06182025_040608.xml","form_type":"4"}}],"next_cursor":"2025-06-18T20:45:12.000000Z,1106502"}